For ARVC, CRISPR-Cas9 has demonstrated the ability to repair mutations in desmosomal genes such as plakophilin 2 (PKP2), thereby restoring normal cardiac function and cellular adhesion. This evidence concerns the gene PKP2 and Arrhythmogenic right ventricular dysplasia.